colorectal cancer

Things that impact racial, ethnic disparities in cancer survivalOne study seeks to understand the underlying causes of racial and ethnic disparities in cancer survival. The results may be surprising.
Pharmacists Recognized for Cancer Screening EffortsThe FIP awards honored two international pharmacy associations for their recent campaigns.
New Cigna program aims to ‘unlock’ the value of healthcare dataCigna publication project takes a page out of the big pharma and medical technology playbook.
Payer-provider partnership drives value: Execs share lessons learnedHumana and Oak Street Health share the challenges and opportunities of moving away from the fee-for-service model to value-based care.
One insurer proves that value-based reimbursement works in practiceHumana’s value-based reimbursement model with physicians has helped to improve care quality and health outcomes for its Medicare Advantage (MA) program members.
FDA approves trifluridine/tipiracil for colorectal cancerLonsurf is a new, orally administered cytotoxic drug for the treatment of patients with metastatic colorectal cancer.
USPSTF updates recommendations for aspirin useThe guidelines, which update the group's 2007 and 2009 recommendations, are published in the "Annals of Internal Medicine."
Does ovary removal increase colorectal cancer risk?Do sex hormone level changes from ovary removal increase colorectal cancer risk? Plus: The CDC releases the newest information on the birth rate among teenagers. Also, a look at the impact of hyperglycemia and excessive weight gain on offspring.
Limb gangrene in cancer patients receiving warfarinVenous limb gangrene can occur in cancer patients, but the clinical picture and pathogenesis aren’t clear.
New treatment approved for advanced colorectal cancerFDA has approved a combination oral therapy of trifluridine and tipiracil (Lonsurf, Taiho Oncology) for patients with metastatic colorectal cancer who were previously treated with chemotherapy and biological therapy.